Drug – bio-affecting and body treating compositions – Designated organic nonactive ingredient containing other... – Carbohydrate or lignin – or derivative
Patent
1994-02-10
1996-06-11
Azpuru, Carlos A.
Drug, bio-affecting and body treating compositions
Designated organic nonactive ingredient containing other...
Carbohydrate or lignin, or derivative
424451, 424456, 424458, 424461, 424474, 424479, 424489, 424493, 424499, 514960, 514965, A61K 948, A61K 964, A61K 936, A61K 950
Patent
active
055256341
ABSTRACT:
A colonic delivery system for delivering a drug to the colon is provided. The system comprises a drug in combination with a matrix, wherein the matrix comprises a saccharide-containing polymer. According to the invention, the matrix is resistant to chemical and enzymatic degradation in the stomach and small intestine. The matrix is degraded in the colon by bacterial enzymatic action, and the drug is released. The system is useful for targeting drugs to the colon in order to treat colonic disease. The system is also useful for enteric administration of drugs such as proteins and peptides which are otherwise degraded in the stomach and small intestine.
REFERENCES:
patent: 4627850 (1986-12-01), Deters et al.
patent: 4863744 (1989-09-01), Urquhart et al.
patent: 4904474 (1990-02-01), Theeuwes et al.
Lancaster et al., "Drug Delivery to the Colon: Polymer Susceptibility to Degradation by Colon Contents", Polymer. Prepr. 30:480-1 (1989).
Rubinstein, A., Biophar. & Drug Disposition 11:465-475 (1990).
Levine, D. S. et al., Gastroenterology 92:1037-1044 (1987).
Rasmussen, S. N. et al., Gastroenterology 83:1062-1070 (1982).
Mardini, H. A. et al., Gut 28:1084-1089 (1987).
Fairbairn, J. W., J. Pharm. Pharmacol. 1:683-694 (1949).
Hardcastle, J. D. et al., Gut 11:1038-1042 (1970).
Cummings, J. H., Gut 15:758-766 (1974).
Moreto, M. et al., Arzneim-Forsch./Drug Res. 29:1561-1564 (1979).
Gullikson, G. W. et al., Pharmacology of Intestinal Permeation II, Csaky, T. Z. (ed.), Springer-Verlag, Heidelberg, pp. 419-459 (1984).
Simpkins, J. W. et al., J. Pharmacol. Exp. Ther. 244:195-205 (1988).
Klotz, U., Clin. Pharmacokin. 10:285-302 (1985).
Willoughby, C. P. et al., Gut 23:1081-1087 (1982).
Bartalsky, A., Lancet 1:960 (1982).
Brown, J. P. et al., J. Med. Chem. 26:1300-1307 (1983).
Cummings, J. H. et al., Am. J. Clin. Nutr. 45:1243-1255 (1987).
Friend, D. R. et al., J. Med. Chem. 28:51-57 (1985).
Saffran, M. et al., Science 233:1081-1084 (1986).
Saffran, M. et al., J. Pharm. Sci. 77:33-38 (1988).
Saffran M. et al., Diabetes 38S:81A (1989).
Mirelman, D. et al., J. Infect. Dis. 159:303-309 (1989).
Salyers, A. A., Amer. J. Cli. Nutr. 32:158-163 (1979).
Salyers, A. A. et al., J. Bacteriol. 143:772-780 (1980).
Friend, D. R. et al., J. Med. Chem. 27:261-266 (1984).
Rachmilewitz, D., Br. Med. J. 298:82-86 (1989).
Supplementary European Search Report to accompany European Application No. 91 91 0743.3, completed Aug. 11, 1993.
Gassmann, B. et al., "Pharmaceutical Composition with Delayed Activity Release", Chemical Abstracts 103(22), Abstract No. 183574c (Jul. 8, 1985).
Lancaster, C. M. et al., Drug Delivery to the Colon: Polymer Susceptibility to Degradation by Colon Contents, Chemical Abstracts 110(22), Abstract No. 199047p (Jan. 2, 1989).
Bartalsky, A., Salicylazobenzoic Acid In Ulcerative Colitis, Lancet:960 (Apr. 24, 1982).
Brown, J. P. et al., A Polymeric Drug for Treatment of Inflammatory Bowel Disease, J. Med. Chem. 26:1300-1307 (1983).
Cummings, J. H. et al., Fermentation in the human large intestine and the available substrates, Am. J. Clin. Nutr. 45:1243-1255 (1987).
Cummings, J. H., Progress Report: Laxative Abuse, Gut 15:758-766 (1974).
Fairbairn, J. W., The Active Constituents Of The Vegetable Purgatives Containing Anthracene Derivatives, J. Pharm. Pharmacol. 1:683-694 (1949).
Friend, D. R. et al., A Colon-Specific Drug-Delivery System Based on Drug Glycosides and the Glycosidases of Colonic Bacteria, J. Med. Chem. 27:261-266 (1984).
Friend, D. R. et al., Drug Glycosides: Potential Prodrugs for Colon-Specific Drug Delivery, J. Med. Chem. 28:51-57 (1985).
Gassman, B. et al., Pharmaceutical Composition with Delayed Activity Release, Chemical Abstracts 103(22), Abstract No. 183574c (Jul. 8, 1985).
Gullikson, G. W. et al., Mechanisms of Action of Laxative Drugs, in Csaky, T. Z., ed., Pharmacology of Intestinal Permeation II, Springer-Verlag, Heidelberg, pp. 419-459 (1984).
Hardcastle, J. D. et al., The Action of Sennosides and Related Compounds on Human Colon and Rectum, Gut 11:1038-1042 (1970).
Klotz, U., Clinical Pharmacokinetics of Sulphasalazine, Its Metabolites and Other Prodrugs of 5-Aminosalicyclic Acid, Clin. Pharmacokinetics 10:285-302 (1985).
Lancaster, C. M. et al., Drug Delivery to the Colon: Polymer Susceptibility to Degradation by Colon Contents, Chemical Abstracts 110(22), Abstract No. 199047p (Jan. 2, 1989).
Levine, D. S. et al., Coating of Oral Beclomethasone Dipropionate Capsules With Cellulose Acetate Phthalate Enhances Delivery of Topically Active Antiinflammatory Drug to the Terminal Ileum, Gastroneterol. 92:1037-1044 (1987).
Mardini, H. A. et al., Effect of Polymer Coating on Faecal Recovery of Ingested 5-Amino Salicylic Acid In Patients with Ulcerative Colitis, Gut 28:1084-1089 (1987).
Mirelman, D. et al., Effects of Covalently Bound Silica-Nitroimidazole Drug Particles on Entamoeba histolytica, J. Infect. Dis. 159(2):303-309 (1989).
Moreto, M. et al., 3,3-Bis-(4-hydroxyphenyl)-7-methyl-2-indolinone (BHMI), the Active Metabolite of the Laxative Sulisatin, Arnzeim. -Forsch./Drug Res. 29:1561-1564 (1979).
Rachmilewitz, D., Coated Mesalazine (5-aminosalicyclic acid) Versus Sulphasalazine in the Treatment of Active Ulcerative Colitis: A Randomised Trial, Brit. Med. J. 298:82-86 (1989).
Rasmussen, S. N. et al., 5-Aminosalicyclic Acid in a Slow-Release Preparation: Bioavailability, Plasma Level, and Excretion in Humans, Gastroenterol. 83:1062-1070 (1982).
Rubinstein, A., Microbially Controlled Drug Delivery To The Colon, Biopharm. Drug Dispos. 11:465-475 (1990).
Saffran, M. et al., A New Approach to the Oral Administration of Insulin and Other Peptide Drugs, Science 233:1081-1084 (1986).
Saffran, M. et al., Oral Insulin in Diabetic Dogs, Diabetes 38S:81A, Abstract No. 324 (1989).
Saffran, M. et al., Vasopressin: A Model for the Study of Effects of Additives on the Oral and Rectal Administration of Peptide Drugs, J. Pharm. Sci. 77(1):33-38 (1988).
Salyers, A. A., Energy Sources of Major Intestinal Fermentative Anaerobes, Am. J. Clin. Nutr. 32:158-163 (1979).
Salyers, A. A. et al., Cellular Location of Enzymes Involved in Chondroitin Sulfate Breakdown by Bacteroides thetaiotaomicron, J. Bacteriol. 143(2):772-780 (1980).
Simpkins, J. W. et al., Evidence for the Delivery of Narcotic Antagonists to the Colon as their Glucuronide Conjugates, J. Pharmacol. Exper. Therap. 244(1):195-205 (1988).
Willoughby, C. P. et al., Distribution and Metabolism in Healthy Volunteers of Disodium Azodisalicylate, a Potential Therapeutic Agent for Ulcerative Colitis, Gut 23:1081-1087 (1982).
Rubinstein Abraham
Sintov Amnon
Azpuru Carlos A.
Perio Products Ltd.
Yissum Research Development Co. of the Hebrew Univ. of Jerusalem
LandOfFree
Colonic drug delivery system does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Colonic drug delivery system, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Colonic drug delivery system will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-351957